On 23 March, the Indian Parliament passed a new Patents Act, which brought the country into compliance with its WTO obligations. Heavily politicised amendment negotiations secured the continuation of pharmaceutical exports to least-developed countries, as well as the right to oppose patent applications on a number of grounds. However, some flexibilities under the TRIPS Agreement were lost.